image credit: Pexels

Astellas, CytomX Launch $1.7B Cancer Immunotherapy Collaboration

Astellas Pharma plans to expand its pipeline of next-gen immuno-oncology treatments through a collaboration with CytomX that could generate more than $1.68 billion for the South San Francisco, CA, developer of antibody therapeutics.

Through the collaboration, announced Monday night, Astellas intends to apply CytomX’s Probody® therapeutic tech platform, proprietary bispecific formats and CD3 molecules to discover, research, develop, and commercialize novel T-cell engaging bispecific antibodies designed to fight cancer by targeting CD3 and tumor surface cell antigens.

Read More on Genetic Engineering and Biotechnology News